Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals
Vanda Pharmaceuticals (VNDA) has disclosed a new risk, in the Regulation category.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vanda Pharmaceuticals faces significant uncertainty in obtaining FDA approval to commercialize key product candidates such as BysantiTM and imsidolimab, despite current NDA and BLA submissions. Prolonged review timelines, potential requests for additional studies, or outright rejection could delay revenues, increase costs, and erode any prospective competitive advantage.
Overall, Wall Street has a Strong Buy consensus rating on VNDA stock based on 3 Buys and 1 Hold.
To learn more about Vanda Pharmaceuticals’ risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.